LUNDBECK TOPS CORPORATE REPUTATION RANKINGS FOR FOURTH CONSECUTIVE YEAR

Annual survey finds Lundbeck US is first among leading pharmaceutical companies in the eyes of patient groups.

Deerfield, Ill., May 31, 2019 – For the fourth straight year, patient groups ranked Lundbeck US, an affiliate of the global pharmaceutical company H. Lundbeck A/S, #1 for corporate reputation. According to the new PatientView Corporate Reputation of Pharma, USA Edition, which is based on a survey of U.S. patient groups, Lundbeck has the best overall corporate reputation among 30 leading pharmaceutical companies.

“To be ranked #1 four years in a row is an incredible honor and a testament to our employees’ unwavering commitment to the patient communities we serve,” said Peter Anastasiou, executive vice president and head of Lundbeck North America. “As the only global pharmaceutical company solely focused on brain health, we feel an intense responsibility to people impacted by brain diseases. Patient-centricity isn’t a passive corporate value; it is at the core of who we are, it is embedded in our company purpose and it motivates every individual at Lundbeck.”

Report highlights

The PatientView report compiles feedback on the performance of pharmaceutical companies on key indicators of corporate reputation. In addition to the overall top ranking, Lundbeck also ranked first in 10 individual categories, as judged by patient groups familiar with the company. These include:

  • Patient-centricity
  • Patient information
  • Patient safety
  • High-quality products
  • Transparency in pricing
  • Transparency in clinical data 
  • Transparency in funding
  • Corporate integrity
  • Quality of patient-group relationships
  • “Beyond the pill” service

Patient groups that work directly with Lundbeck gave the company especially high marks.

  • 60 percent ranked Lundbeck #1 on quality of relationships
  • 50 percent ranked Lundbeck first for “beyond-the-pill” services
  • 46.7 percent identified the company as having the “most effective patient-centered strategy”
  • 46.7 percent identified the company as having the “most integrity” 

Lundbeck’s patient-centricity

In 2018, Lundbeck partnered with 27 different patient groups, and the company’s approximately 750 U.S. employees participated in more than 600 patient advocacy events across the country. “Patient advocacy is embedded into our culture and our employees embrace the opportunity to engage with patient communities,” Anastasiou said. “We also regularly engage with patient groups in more organized ways, convening representatives of patient communities to help us understand gaps in treatment and the functional outcomes that matter most to patients.”

One example of the company’s close collaboration with patient groups was the highly successful 2018 launch of “Sidekicks™: Uniting Youth and People with Parkinson’s.” This unique intergenerational program, developed in partnership with the Davis Phinney Foundation and in collaboration with leading Parkinson’s patient and research organizations, brings together adults with Parkinson's and school-aged youth in a series of interactive art and story-sharing workshops. Because Parkinson’s can impact the activities of daily living, some people may develop a feeling of isolation if they are spending less time with friends and loved ones. Sidekicks helps people with Parkinson’s share their experiences while fostering positive, meaningful connections with youth. In 2018, Sidekicks brought together 100 youth and people with Parkinson’s across five pilot programs. The program was so well received, it is expanding to 10 markets this year.

“Lundbeck is a true leader in collaborating with advocacy organizations,” said Polly Dawkins, executive director of the Davis Phinney Foundation.  “They listen and deeply respect the needs of the Parkinson’s community, and then they help to advance innovative programs.  We are proud to call them a partner.”

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. 

In the U.S., Lundbeck employs approximately 750 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in a broad range of initiatives each year that support our patient communities. For additional information, we encourage you to visit at www.lundbeckus.com, subscribe to our newsletter at Newsroom.LundbeckUS.com and connect with us on Twitter at @LundbeckUS.

Lundbeck Media Contact:

Molly Brennan
Senior Manager, Corporate Communications
MLLY@lundbeck.com